Charles T. Liamos Joins Insulet Corporation's Board Of Directors

BEDFORD, Mass, Feb. 14 /PRNewswire/ -- Charles T. Liamos, President and CEO of FoviOptics, Santa Clara, California, has joined the Board of Directors of Insulet Corporation, manufacturers of the OmniPod(R) Insulin Management System. The OmniPod Insulin Management System is an innovative, new product for the treatment of diabetes that brings together safe, reliable continuous subcutaneous insulin infusion and blood glucose monitoring in an easy-to-use, two-part system.

In announcing the appointment, Duane DeSisto, Insulet Corporation President and CEO, said, "Charlie Liamos brings to our Board more than 10 years of experience as a senior operations manager and corporate executive in the diabetes-care industry. We value his experience highly as we drive this company to the next stage in its evolution."

"I'm thrilled to be joining the team at Insulet to make this innovative product available to people living with diabetes," Liamos said. "The OmniPod System brings a new level of convenience, discretion and freedom to the treatment of diabetes, a potentially devastating disease."

Before joining FoviOptics, Liamos served as Chief Operating Officer and Chief Financial Officer of TheraSense, Inc., and served on its Board of Directors. When Abbott Laboratories acquired TheraSense in 2004, Liamos was named Group Vice President of Business Operations for Abbott Diabetes Care, and served on the committee that integrated TheraSense into its new parent company.

Before that, he worked in operations management at LifeScan, a division of Johnson & Johnson. He began his career at General Electric.

Liamos earned a B.S. in Finance from the University of Vermont, Burlington and is a graduate of GE's Financial Management Program.

He joins these executives on Insulet Corporation's Board of Directors: * Juliet Tammenoms Bakker, General Partner, Pequot Ventures * Alison de Bord, Principal, Alta Partners * Duane DeSisto, President and Chief Executive Officer, Insulet Corporation * Gary Eichhorn, Former General Manager, Hewlett Packard Medical Products Group * Ross A. Jaffe, M.D., Managing Director, Versant Ventures * Gordie Nye, General Partner, Prism Venture Partners About Insulet Corporation

Founded in August 2000, Insulet Corporation is a privately-held, innovative diabetes management company dedicated to providing superior treatment options and lifelong health benefits for people with diabetes. Insulet Corporation employees have extensive knowledge and experience in the diabetes and medical device industries. The company seeks to improve the lives of people with diabetes through technology and communication with healthcare professionals and those personally afflicted.

Insulet Corporation's first commercial product, the OmniPod(R) Insulin Management System, has been specifically designed to break down the barriers to continuous subcutaneous insulin infusion therapy, improve health outcomes, and make diabetes a smaller part of life for diabetes patients. The OmniPod Insulin Management System received 510(k) clearance from the U.S. Food and Drug Administration in January 2005, and is currently available in the United States.

Contact: Hugh Ryan Ryan Wellnitz & Associates 401.246.2300 hryan@ryanwellnitz.com

CONTACT: Hugh Ryan of Ryan Wellnitz & Associates for Insulet Corporation,+1-401-246-2300, hryan@ryanwellnitz.com

Web site: http://www.MyOmniPod.com/